FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL

Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older

HRV Pharma unveils brand mascots

Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership

Celonic and Carbogen Amcis partner to deliver ADC development and manufacturing platform

PromoCell launches custom GMP cell culture media to power next-gen cell and gene therapies

New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain

AGC Pharma Chemicals opens new €100 million manufacturing plant in Spain

It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients

Lilly to invest $1 billion+ in new contract manufacturing in India

Investment to expand manufacturing and global medicine supply capacity

Nanavati Max, Uzbekistan’s NVRH forge alliance to advance healthcare and training

Amgen’s Phase III data supports FDA label expansion of Repatha

Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention

FDA approves Roche’s Tecentriq + lurbinectedin as first-line maintenance therapy for lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study

AbbVie’s Natrelle awarded supplier agreement from Vizient

This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market